和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

休市中 09-18 16:08:32

21.540

-0.260

-1.19%

最高22.300	最低21.460	成交量668.85万
今开22.000	昨收21.800	日振幅3.85%
总市值187.83亿	流通市值187.83亿	总股本8.72亿
成交额1.45亿	换手率0.77%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":21.54,"timestamp":1789718912003,"preClose":21.8,"halted":0,"volume":6688500,"delay":0,"changeRate":-0.011926605504587228,"floatShares":872000000,"shares":872000000,"eps":4.079415387270631,"marketStatus":"休市中","change":-0.26,"latestTime":"09-18 16:08:32","open":22,"high":22.3,"low":21.46,"amount":144891490,"amplitude":0.038532,"askPrice":21.58,"askSize":3500,"bidPrice":21.54,"bidSize":63000,"shortable":3,"etf":0,"ttmEps":0.15839145203931937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789954200000},"marketStatusCode":7,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":21.8,"openAndCloseTimeList":[[1789695000000,1789704000000],[1789707600000,1789718400000]],"volumeRatio":1.0368620302560503,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013/tweets","defaultTab":"tweets","newsList":[{"id":"2668195427","title":"港股异动 | 和黄医药(00013)尾盘涨超3% ATTC授权GSK 机构指公司出海路径清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2668195427","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668195427?lang=zh_cn&edition=full","pubTime":"2026-09-17 15:26","pubTimestamp":1789629963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和黄医药尾盘涨超3%。截至发稿，涨2.72%，报21.9港元，成交额9056.96万港元。消息面上，9月3日，公司公告与GSK就HMPL-A830达成独家许可协议，GSK以首付款/里程碑1.1/11.85亿美元获海外权益。华福证券表示，看好HMPL-A830有望以差异化机制切入CRC的KRAS突变未满足市场，建议重点跟踪I期数据读出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","00013","BK1191","BK1588","BK1587","KCAI","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342123","title":"中金：维持和黄医药(00013)“跑赢行业”评级 目标价升至28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665342123?lang=zh_cn&edition=full","pubTime":"2026-09-08 13:37","pubTimestamp":1788845857,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持和黄医药“跑赢行业”评级，上调目标价7.7%至28港元。考虑到本次交易于今年达成，该行调整2026年及2027年确认收入节奏，上调2026年净利润预测41%至7,807万美元，下调2027年净利润预测25%至6,638万美元。和黄医药近日公告与葛兰素史克达成独家开发和许可协议，将HMPL-A830除中国以外的全球开发和商业化权益授予GSK。该行认为GSK是有力合作伙伴，并指ATTC平台获跨国药企背书，除HMPL-A830外，PI3K/PIKK系列管线亦具备看点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665062393","title":"一个还没进临床的分子，凭什么卖出12.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665062393","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665062393?lang=zh_cn&edition=full","pubTime":"2026-09-07 10:08","pubTimestamp":1788746914,"startTime":"0","endTime":"0","summary":"对一款尚未进入人体临床试验的资产而言，1.1亿美元的首付款属于明显偏高的定价。2023年，和黄医药将已在中国获批上市的呋喹替尼授权给武田制药：总额11.3亿美元，首付款4亿美元。那是\"成熟产品出海\"的典范，一个经过临床验证、获批上市的分子，换取全球市场权益。HMPL-A830尚未启动I期临床，和黄医药卖的是一个\"概念验证前\"的平台资产，而12.95亿美元的总交易额，已经超过了呋喹替尼的11.3亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788491648644278418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4080","KURE","ADC","BK1587","BK1191","00013","NETL","BK1588","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664330739","title":"总额可达12.95亿美元，和黄医药BD落地，管理层回应市场疑虑：借助合作加速开发，但不会调整整体战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2664330739","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664330739?lang=zh_cn&edition=full","pubTime":"2026-09-04 22:40","pubTimestamp":1788532800,"startTime":"0","endTime":"0","summary":"“HMPL-A830是我们创新有效载荷平台下的第三款候选药物，也是继前两款候选药物进入临床开发后，我们平台旗下首个授权予全球合作伙伴的候选药物”，和黄医药管理层这样定义9月3日上午官宣的合作交易。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043865728649.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043865728649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","00013","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664384254","title":"花旗：上调和黄医药(00013)目标价至39港元 维持“买入/高风险”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664384254","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664384254?lang=zh_cn&edition=full","pubTime":"2026-09-04 14:58","pubTimestamp":1788505097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，将和黄医药(00013)目标价由36港元上调至39港元，维持“买入/高风险”评级。该行同时上调公司2026至2028年肿瘤/免疫业务收入预测27%、26%及14%，每股盈利预测上调至0.08、0.09及0.13美元。和黄医药与GSK就HMPL-A830(KRAS-EGFR ATTC)达成授权协议。花旗认为，GSK的认可验证了ATTC平台概念，且交易较该行预期更早达成。另外，花旗预计HMPL-A251及HMPL-A580于今年底至明年初首次患者给药，届时更多人体数据将进一步验证ATTC平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00013","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664389940","title":"大行评级丨里昂：维持和黄医药“跑赢大市”评级，ATTC平台获跨国药企认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664389940","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664389940?lang=zh_cn&edition=full","pubTime":"2026-09-04 13:18","pubTimestamp":1788499093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["00013","BK1588","BK1587","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385549","title":"大行评级丨大和：上调和黄医药目标价至28.5港元，评级一举升至“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385549","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664385549?lang=zh_cn&edition=full","pubTime":"2026-09-04 10:53","pubTimestamp":1788490409,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["00013","BK1587","EWH","BK1588","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388725","title":"港股异动 | 和黄医药(00013.HK)再涨超6% 与GSK达成12.95亿美元合作 ATTC平台全球价值得到验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388725?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:36","pubTimestamp":1788485764,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","00013","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107128857","title":"异动解读｜和黄医药盘中上涨5.3%，与葛兰素史克达成最高12.95亿美元授权合作提振延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1107128857","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107128857?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485702,"startTime":"0","endTime":"0","summary":"9月4日，和黄医药盘中上涨5.3%，报23.26港元，成交额1.14亿港元，延续前一交易日强势表现。协议包含1.1亿美元首付款，叠加开发、注册及商业化里程碑付款，总额最高可达12.95亿美元，另含基于净销售额的特许权使用费。该消息于前一交易日已推动股价大涨逾16%，今日涨势为市场对这一重磅授权合作的情绪延续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药强势上涨，与葛兰素史克达成重磅授权合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","LU1880383366.USD","01952","06160","LU0039217434.USD","02596","06990","IE00B543WZ88.USD","01093","BK1209","09926","BK1515","BK1161","06996","HK0000306685.HKD","LU0348783233.USD","KCE","LU2543165471.USD","02269","SG9999004220.SGD","HK0000320264.USD","01177","01951","02273","03692","02096","BK1589","LU1242518857.USD","00013","LU0315179316.USD","09996","KURE","06078","LU0856984785.SGD","LU1251922891.USD","LU0327786744.USD","02268","01530","03329","LU0588546209.SGD","02162","01548","03759","IE00B0JY6N72.USD","IE00B5MMRT66.SGD","LU1152091168.USD","01801","06821","LU0307460666.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487004","title":"美股异动 | 和黄医药大涨逾14%，与葛兰素史克就癌症药物达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487004","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664487004?lang=zh_cn&edition=full","pubTime":"2026-09-03 22:54","pubTimestamp":1788447250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，$和黄医药$大涨逾14%。消息面上，和黄医药宣布，附属公司$和记黄埔$医药(上海)与$葛兰素史克$的附属公司达成一项独家开发及许可协议，授予葛兰素史克附属公司除中国内地、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。","market":"hk","thumbnail":"https://static.tigerbbs.com/e8d661c091a8481cd22d8367521ba484","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e8d661c091a8481cd22d8367521ba484"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491805.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和黄医药与葛兰素史克就癌症药物达成许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","BK1587","00013","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664960827","title":"总额可达12.95亿美元！和黄全球首创偶联药物出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2664960827","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664960827?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:03","pubTimestamp":1788422625,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药（00013.HK）宣布旗下子公司和记黄埔与葛兰素史克（GSK）附属公司达成独家开发及许可协议，授予后者除中国大陆、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。协议包括1.1亿美元的首付款以及潜在的开发、注册和商业化里程碑付款，总额可达12.95亿美元，外加基于净销售额的特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864044420.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864044420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1587","BK4585","BK4588","GSKH","LU1829250122.USD","BK4007","BK4532","BK1191","00013","GSK","GSK.UK","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124565155","title":"和黄医药午后飙升逾16%，与葛兰素史克达成最高12.95亿美元肿瘤药授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1124565155","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124565155?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:56","pubTimestamp":1788422188,"startTime":"0","endTime":"0","summary":"$和黄医药(00013)$周四午后股价大幅走高，一度升逾16%，势创2022年11月以来最大单日升幅。消息面上，和黄医药周四宣布，旗下公司与$葛兰素史克(GSK)$附属公司签署独家开发及许可协议，双方将合作开发及商业化在研肿瘤药物HMPL-A830。根据协议，和黄医药将获得1.1亿美元首付款，并有权获得最高12.95亿美元的开发、监管及商业化里程碑付款，以及产品上市后的净销售额特许权使用费。受大额授权合作消息刺激，和黄医药午后获资金明显追捧，股价升幅迅速扩大。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","GSK","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827853","title":"港股异动丨和黄医药放量拉升大涨超16%，与葛兰素史克就癌症药物达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827853","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664827853?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:47","pubTimestamp":1788421621,"startTime":"0","endTime":"0","summary":"和黄医药午后股价拉升，一度涨超16%至22.3港元，截至目前成交额放大至6.5亿港元。消息面上，和黄医药宣布，附属公司和记黄埔医药(上海)与葛兰素史克的附属公司达成一项独家开发及许可协议，授予葛兰素史克附属公司除中国内地、香港、澳门和台湾以外的全球范围内开发和商业化HMPL-A830的权利。临床开发将首先聚焦于结直肠癌、胰腺癌和肺癌适应症。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/03/20260903435792.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/03/20260903435792.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260903/32358949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["KCAI","VXUS","BK1191","BK1588","00013","BK4588","BK4585","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664282466","title":"首付款1.1亿美元，和黄医药与葛兰素史克达成授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664282466","media":"上观新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664282466?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:51","pubTimestamp":1788418291,"startTime":"0","endTime":"0","summary":"9月3日，解放日报记者从和记黄埔医药（上海）有限公司（简称：和黄医药）获悉，他们与葛兰素史克的附属公司达成一项独家开发及许可协议，授予其除中国内地、香港、澳门和台湾以外的全球范围内，对于和黄医药全球首创的一款抗体靶向偶联候选药物HMPL-A830进行开发和商业化运作的权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033863998985.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033863998985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK1588","00013","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664299108","title":"港股异动 | 和黄医药(00013.HK)午后涨幅扩大逾15% 与GSK就KRAS-EGFR抗体偶联癌症药物达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664299108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664299108?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:36","pubTimestamp":1788413764,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1587","BK1588","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143382338","title":"异动解读｜和黄医药盘中上涨8.36%，与葛兰素史克达成KRAS靶向偶联药物全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1143382338","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143382338?lang=zh_cn&edition=full","pubTime":"2026-09-03 13:00","pubTimestamp":1788411645,"startTime":"0","endTime":"0","summary":"9月3日，和黄医药盘中上涨8.36%，报20.82港元，成交额4875.17万港元。消息面上，公司当日公告，旗下和记黄埔医药（上海）与GSK附属公司签署独家开发及许可协议，授予对方在中国内地、港澳台以外全球范围内开发和商业化HMPL-A830的权利。HMPL-A830为全球首创的KRAS-EGFR抗体靶向偶联药物，首批适应症聚焦结直肠癌、胰腺癌和肺癌。根据协议条款，公司将获得1.1亿美元预付款，后续里程碑付款最高可达约13亿美元，另含基于销售业绩的特许权使用费。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和黄医药大涨，与GSK达成重磅全球许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826885","title":"和黄医药(00013)：与葛兰素史克就KRAS-EGFR抗体偶联癌症药物达成许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826885","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664826885?lang=zh_cn&edition=full","pubTime":"2026-09-03 12:11","pubTimestamp":1788408702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 发布公告，其附属公司和记黄埔医药(上海)有限公司与GSK plc的附属公司达成一项独家开发及许可协议，授予该葛兰素史克附属公司除中国内地、中国香港、中国澳门和中国台湾以外的全球范围内开发和商业化HMPL-A830的权利 。结直肠癌、肺癌和胰腺癌是KRAS基因改变发生率最高的癌症类型，这些患者往往缺乏安全且持久的KRAS疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和黄医药(00013)：与葛兰素史克就KRAS-EGFR抗体偶联癌症药物达成许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1588","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1181104507","title":"和黄医药（00013）与葛兰素史克签署HMPL-A830全球独家许可协议 最高交易总额达12.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1181104507","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181104507?lang=zh_cn&edition=full","pubTime":"2026-09-03 12:05","pubTimestamp":1788408350,"startTime":"0","endTime":"0","summary":"2026年9月3日，和黄医药公告称，其全资附属公司和记黄埔医药（上海）有限公司已与GSK plc附属公司GlaxoSmithKline Intellectual Property  Limited签署独家开发及许可协议，对方将获得除中国内地、香港、澳门及台湾地区以外全球范围内的HMPL-A830研发和商业化权利。HMPL-A830为全球首创的KRAS-EGFR抗体靶向偶联药物，临床开发预计于2026年下半年启动，首批适应症聚焦结直肠癌、胰腺癌和肺癌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132698645","title":"和黄医药达成重磅协议：1.1亿美元预付款入账，里程碑付款高达13亿美元，另有销售提成","url":"https://stock-news.laohu8.com/highlight/detail?id=1132698645","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132698645?lang=zh_cn&edition=full","pubTime":"2026-09-03 12:03","pubTimestamp":1788408182,"startTime":"0","endTime":"0","summary":"和黄医药（中国）近日宣布签署一项重大合作协议。根据协议条款，该公司将获得1.1亿美元的 upfront 预付款，这笔资金将立即到账。除此之外，协议的潜在总价值相当可观——若所有里程碑节点均顺利达成，后续里程碑付款总额最高可达13亿美元。更为值得关注的是，协议中还包含了基于未来销售业绩的特许权使用费安排，这为和黄医药提供了持续性的收入来源。整个交易结构设计精巧，既保证了短期的现金流支撑，又为长期发展预留了广阔的业绩增长空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1588","BK1191","00013"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.0528},{"period":"1month","weight":0.1086},{"period":"3month","weight":0.3118},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.2133},{"period":"ytd","weight":0.0446}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.0292},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0208},{"period":"1year","weight":-0.0676},{"period":"ytd","weight":-0.0343}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.066388},{"month":2,"riseRate":0.6,"avgChangeRate":0.075835},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093928},{"month":4,"riseRate":0.4,"avgChangeRate":0.010831},{"month":5,"riseRate":0,"avgChangeRate":-0.149846},{"month":6,"riseRate":0.4,"avgChangeRate":0.004362},{"month":7,"riseRate":1,"avgChangeRate":0.132805},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.047962},{"month":9,"riseRate":0.666667,"avgChangeRate":0.014793},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}